Sudha Kodali
Research Subjects
Research Interests
Sudha Kodali has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Akshay Shetty
Department of Medicine, Division of Hepatology, David Geffen School of Medicine at UCLA; Department of Surgery, Division of Liver and Pancreas Transplantation, David Geffen School of Medicine at UCLA
1 shared publication - David W. Victor
JC Walter Jr Transplant Center, Houston Methodist Hospital, Houston, TX
1 shared publication Fanny Giron
1 shared publicationMuhammad I. Ahmad
1 shared publication- Mukul K. Divatia
Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston Texas USA
1 shared publication
Latest Publications
- Open Access
- 17 May 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Nonalcoholic Fatty Liver Disease after Liver Transplant
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.
- 17 May 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessNonalcoholic Fatty Liver Disease after Liver Transplant
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.